Generation of Biological Samples Positive to Testosterone for Anti-doping Control

• Status: Completed
• Trial end date: 2020-02-26
• Target enrollment: 0
• Participant gender: Male

Summary

Background:

Testosterone is a steroid widely known to improve physical performance due to its protein-anabolic effect. Like other androgenic anabolic steroids (EAA), testosterone is included on the World Anti-Doping Agency (WADA) list of prohibited substances.

EAA are the most detected banned substances in anti-doping controls. Therefore, different analytical strategies are required to improve its detection.

Hypothesis:

The intramuscular administration of 250 mg of testosterone (cypionate) in healthy subjects allows generating detectable concentrations of the drug in urine. Positive urine samples will enable to identify analytical strategies for doping control.

Objectives:

Primary objective: To measure the concentrations of testosterone in urine for anti-doping control samples.

Secondary objective: To identify metabolites and precursors of testosterone in urine. To assess safety and tolerability of the drug used.

Methods:

Phase I, open, non-randomized clinical trial, with a treatment condition (testosterone) administered via intramuscular injection to 4 subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Parc de Salut Mar
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Male volunteers aged between 18 and 50 years.

• Able to understand and accept the trial procedures and able to sign an informed consent.

• History and physical examination that demonstrate not presenting organic or psychiatric disorders.

• ECG, blood and urine tests performed before the test within normal limits. Minor or occasional variations of these limits will be allowed if, in the opinion of the Principal Investigator and taking into account the state of science, they have no clinical significance, do not pose a risk to the subject and do not interfere in the product evaluation. These variations and their non-relevance will be specifically justified in writing.

• Body mass index (weight/height^2) between 19 and 25 kg/m2 and weight between 50 and 90 kg. BMI between 25 and 27 kg/m2 may be included according to Principal Investigator's criteria.

Exclusion Criteria:

• History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active substance or similar nonapeptides, or to any of the excipients.

• Patient with history or current presence of breast cancer, liver cancer, or suspicion or confirmation of prostate carcinoma.

• History or current presence of prostate syndrome symptoms: frequent urination (both day and night), difficulty in starting urination, weak or discontinuous urinary stream, feeling of incomplete bladder emptying, or benign prostatic hyperplasia diagnosis.

• Levels of prostate specific antigen (PSA) > 4 ng/mL.

• Hematocrit value >50%.

• Patients with acute abdominal pain of unknown origin.

• Clinical background or evidence of gastrointestinal, hepatic, renal disorder or others that may involve an alteration of the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.

• Clinical background or evidence of psychiatric disorders, alcoholism, drug abuse or habitual consumption of psychoactive drugs.

• Having participated in another clinical trial with medication in the three months prior to the start of the study.

• Having suffered some organic disease or major surgery in the six months prior to the start of the study.

• Clinical background or evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological, neurological or other acute or chronic diseases that, in the opinion of the Principal Investigator or the collaborators designated by him/her, may pose a risk to the subjects or may interfere with the objectives of the study. Especially history of venous thrombosis or thromboembolic disorders, thrombophilic alteration, edema, hypercalcemia, polycythemia, nephrosis, liver disease with altered liver function tests and porphyria.

• Having taken medication regularly in the month prior to the study sessions. Treatment with single doses of symptomatic medication in the week prior to the study sessions will not be a reason for exclusion if it is assumed that the drug has been completely eliminated on the day of the experimental session.

• Smokers of more than 20 cigarettes a day in the 3 months before the study.

• Consumption of more than 40 g of alcohol daily.

• Consumers of more than 5 coffees, teas, cola drinks, or other stimulant drinks or with xanthines daily in the 3 months prior to the study start.

• Being unable to understand the nature, consequences of the trial and the procedures that are asked to follow.

• Positive serology for hepatitis B, C or HIV.